First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

NCT ID: NCT03287310

Last Updated: 2021-03-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-17
• Study Completion Date: 2019-07-31

Brief Summary

GSK3511294 is a humanized monoclonal antibody antagonist of Interleukin (IL)-5 which is known to block binding of IL-5 to the IL-5 receptor complex, causing a reduction in the circulating population of eosinophils. This is a single ascending dose FTIH study to investigate safety, tolerability, immunogenicity, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3511294, administered SC in subjects with mild to moderate asthma maintained on a low-medium daily dose of inhaled corticosteroids (ICS) or ICS/long acting beta-agonist (LABA), and short acting beta-agonist (SABA). The subjects will attend a pre-screen visit of up to 12 weeks before dosing for assessment of blood eosinophils. Eligible subjects with blood eosinophils >=200 cells per microliter (cells/µL) will undergo a screening period of up to 4 weeks. The subjects will then be randomized into 5 cohorts. In each cohort, the subjects will be randomized to receive a single dose of GSK3511294 or placebo in a ratio of 3:1. The follow-up period will be up to 40 weeks post dose and will be dose-dependent. The scheduled maximum duration for each subject will be up to 44 weeks including up to 28 days of screening.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Subjects receiving GSK3511294 in Cohort 1

Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.

Group Type: EXPERIMENTAL

GSK3511294

Intervention Type: DRUG

GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving placebo in Cohort 1

Two subjects in Cohort 1 will receive a single SC dose of placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving GSK3511294 in Cohort 2

Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.

Group Type: EXPERIMENTAL

GSK3511294

Intervention Type: DRUG

GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving placebo in Cohort 2

Two subjects in Cohort 2 will receive a single SC dose of placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving GSK3511294 in Cohort 3

Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.

Group Type: EXPERIMENTAL

GSK3511294

Intervention Type: DRUG

GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving placebo in Cohort 3

Three subjects in Cohort 3 will receive a single SC dose of placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving GSK3511294 in Cohort 4

Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.

Group Type: EXPERIMENTAL

GSK3511294

Intervention Type: DRUG

GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving placebo in Cohort 4

Three subjects in Cohort 4 will receive a single SC dose of placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving GSK3511294 in Cohort 5

Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.

Group Type: EXPERIMENTAL

GSK3511294

Intervention Type: DRUG

GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Subjects receiving placebo in Cohort 5

Two subjects in Cohort 5 will receive a single SC dose of placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.

Salbutamol/albuterol

Intervention Type: DRUG

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Interventions

GSK3511294

GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.

Intervention Type: DRUG

Placebo

Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.

Intervention Type: DRUG

Salbutamol/albuterol

Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects should be between 18 and 65 years of age inclusive, at the time of signing the informed consent.
• Blood eosinophils of >= 200 cells/µL at screening.
• A physician diagnosis of asthma (mild or moderate, as defined by the Global Initiative for Asthma [GINA], 2017) at least 12 months prior to the start of the study. The reason for diagnosis of asthma should be documented in the subject's source data, including relevant history and investigations - specifically evidence of airway hyper-responsiveness, airflow variation (peak flow rate or forced expiratory volume in one second [FEV1]) or reversible airflow obstruction should also be documented in the subject's source data.
• A screening pre-bronchodilator FEV1 >= 60% of predicted normal value.
• Asthma Control Test score > 19.
• hsCRP of < 10 milligrams per liter (mg/L) at screening.
• Otherwise healthy (other than the acceptable conditions of asthma and other atopic diseases, including allergic rhinitis and atopic dermatitis) based on a screening medical history, physical examination, vital signs, ECG assessment, pulmonary function testing, and clinical laboratory results.
• Maintained controlled on as needed SABA and one of the following: a) stable dose of ICS; b) stable dose of combination therapy: ICS/LABA.
• Body weight >= 50 kilograms (kg), and body mass index (BMI) of 19-32 kilograms per square meter (kg/m^2) inclusive.
• Male and female subjects. a) a female subject is eligible to participate if she is not pregnant, not breastfeeding, and not a woman of childbearing potential. b) as GSK3511294 is a monoclonal antibody that is not anticipated to interact directly with Deoxyribonucleic acid (DNA) or other chromosomal material with minimal exposure through semen expected, male subjects will not be required to use contraception during the study, nor are they prohibited from donating sperm.
• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions of the study.

Exclusion Criteria

• Any asthma exacerbation requiring systemic corticosteroids within 12 weeks of screening, or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to screening.
• A history of life-threatening asthma defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years.
• Significant pulmonary diseases, other than asthma, including (but not limited to): pneumonia previously requiring hospital admission, pulmonary fibrosis, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other significant respiratory abnormalities.
• Suspected or confirmed bacterial or viral infection (including tuberculosis) of the upper or lower respiratory tract, sinus or middle ear that occurred within and/or has not resolved within 4 weeks of screening that: led to a change in asthma management or in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
• Positive for hepatitis B surface antigen (HBsAg) at screening.
• Positive hepatitis C antibody test result at screening, or within 3 months prior to first dose of study treatment.
• Known immunodeficiency (other than that explained by the use of corticosteroids), including a positive test for human immunodeficiency virus (HIV) antibody at screening.
• Latent or chronic infections (example, genital herpes, urinary tract infections) or at risk of infection (example, significant trauma or infection within the 90 days before screening).
• Opportunistic infection within 6 months prior to screening (example, a non-tuberculous mycobacterial infection or cytomegalovirus, pneumocystosis, aspergillosis).
• Parasitic infestation within 6 months prior to screening, or have travelled to a country with a high prevalence of such infections in the 6 months before screening, or intend to do so in the year after dosing.
• Live vaccine within 4 weeks prior to screening, or intention to receive live vaccine during the study.
• Corrected QT by Fridericia's formula (QTcF) interval > 450 milliseconds (msec)
• A personal history of severe hypertension, arrhythmia, Right Bundle Branch Block, or Left Bundle Branch Block, or a family history of sudden unexplained death, long QT, familial cardiac syndrome, or cardiomyopathy.
• ALT >1.5 times upper limit of normal (ULN).
• Bilirubin >1.5 times ULN. Isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%.
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• Any history or presence of clinically relevant cardiac or cardiovascular, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease or immunodeficiency, or signs of acute illness, or any other illness or condition that, in the opinion of the investigator (in consultation with the medical monitor), would adversely affect the subject's participation in this study.
• A previous history of cancer in remission for less than 5 years prior to screening (except for localized carcinoma of the skin that had been resected for cure) or current malignancy.
• A positive drug/alcohol test before dosing, OR any history of drug abuse OR regular alcohol consumption within 6 months of the study defined as: An average weekly intake of > 14 units alcohol. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (equivalent to 240 milliliters [mL]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
• Current smokers or ex-smokers who have given up smoking for < 12 months and/or have a smoking pack history of > 5 pack years (1 pack year = 20 cigarettes per day for 1 year or 5 cigarettes per day for 4 years).
• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
• Anticipated non-availability and/or risk of non-compliance with study visits and procedures, or unwillingness or inability to follow the study specific procedures.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day.
• History of sensitivity to any of the study medications, or its components, or a history of drug reaction or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
• Major surgery within 90 days prior to screening, or planned in-patient surgery or hospitalization during the study period
• Donation or loss of blood or blood products in excess of 500 mL within the 3 months before dosing.
• History of renal disease, abnormal kidney function or evidence of persisting or clinically relevant protein or blood on urinalysis.
• History or signs of immunologically active disease (including the presence of low C3 or low C4) or thrombocytopenia.
• History of vasculitis.
• Subjects are excluded if they are undergoing desensitization therapy, or have received any of the following medications as indicated prior to screening: anti- Immunoglobulin E (IgE) therapy (within 6 months); anti-IL5 (within 6 months); oral or injectable corticosteroids (within 8 weeks); long acting muscarinic antagonist (LAMA) or leukotriene receptor antagonist (LTRA) therapy (within 8 weeks); drugs that can prolong the QT interval.
• Subjects who are employees of the sponsor or clinical unit are excluded.
• Vulnerable subjects, e.g., participants kept in detention, protected adults under guardianship, trusteeship and soldiers, or participants committed to an institution by governmental or juridical order.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Hanover, Lower Saxony, Germany

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Harrow, Middlesex, United Kingdom

GSK Investigational Site

London, , United Kingdom

GSK Investigational Site

Manchester, , United Kingdom

Countries

Germany; United Kingdom

References

Singh D, Fuhr R, Bird NP, Mole S, Hardes K, Man YL, Cahn A, Yancey SW, Pouliquen IJ. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712. doi: 10.1111/bcp.15002. Epub 2021 Aug 24.

Reference Type: DERIVED

PMID: 34292606 (View on PubMed)

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

2016-004256-30

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

205722

Identifier Type: -

Identifier Source: org_study_id